178 episodes

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

Molecule to Market: Inside the outsourcing space Raman Sehgal

    • Science
    • 5.0 • 31 Ratings

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

    Harnessing tech to improve the economics of making medicine

    Harnessing tech to improve the economics of making medicine

    In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

    Why being a supplier is harder if you have not been on the client side

    An industry driven by change and the importance of digital strategy to drive business outcomes

    Why pharma companies need to be both big and fast to win

    How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks

    The future of deployable, modular factories to service population centers that provide better access to personalized medicines

    How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)

    David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.

    In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.

    LinkedIn: (6) David Staunton | LinkedIn

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

    • 52 min
    Tasty Topics: Addressing the potential impact of the BIOSECURE Act

    Tasty Topics: Addressing the potential impact of the BIOSECURE Act

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
    Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
    Hanna Lesch, Chief Technology Officer at Exothera 
    Stephen Grant, entrepreneurial advisor and angel investor
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:
    Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
    Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
    How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
    What impacts BIOSECURE will have on the supply chain 
     
    The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.
     
    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
     
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 34 min
    Becoming...a world class scientific leader

    Becoming...a world class scientific leader

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:

    How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space

    What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen

    Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side

    The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients

    The advisory and execution role of a CDMO partner

    Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.

    Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.

    Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 44 min
    Mission-driven doctor, inventor & entrepreneur

    Mission-driven doctor, inventor & entrepreneur

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering:

    How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space

    The journey from inventors to becoming a commercial pharma company... followed by a $310m exit

    How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived

    The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing

    The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to access

    As CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines.

    He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President.

    Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications.

    As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 55 min
    The boomerang boy impacting gene therapies

    The boomerang boy impacting gene therapies

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:
    Growing a CDMO while dealmaking in a gene therapy company…at the same time
    Selling a revenue-generating therapy company to Bayer during the pandemic
    Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
    The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 
    Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 
    Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.
    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

    • 56 min
    Taking on the biologics CDMOs from down under

    Taking on the biologics CDMOs from down under

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark W. Womack, Chief Executive Officer at BioCina.
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:
    How a tough upbringing in LA led him to the US Navy, and then onto a pathway into leadership
    Why he decided to end his own practice and jump into a senior role within a biopharma CDMO space
    The key factors that led him to relocate to Adelaide, Australia
    The reality that most biologics CDMOs frequently fail to deliver... and why winning requires operating with discipline, and consistently executing at a high level
    Mark W. Womack is BioCina’s Chief Executive Officer. Prior to BioCina, he was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMOs, he led them to nearly a 300% increase in new sales in just two years.
    Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors and numerous transformations that generated more than $100M in certified client benefits.
    Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy’s highest honors and awards.
    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
     

    • 50 min

Customer Reviews

5.0 out of 5
31 Ratings

31 Ratings

JCHOT$$ ,

Great podcast

Really enjoy listening to the content on this show and hearing all of the amazing work happening in this space.

Maryhuston ,

Awesome!

Truly awesome to listen Raman’s shows. He brings out the best of the bests. Thoroughly enjoy his show! Good luck Raman!

C-Lo-77 ,

Great insights!

Raman does a wonderful job with capturing insights across the industry and with experts.

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Short Wave
NPR
StarTalk Radio
Neil deGrasse Tyson
Radiolab
WNYC Studios
Ologies with Alie Ward
Alie Ward
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network

You Might Also Like

a16z Podcast
Andreessen Horowitz
Acquired
Ben Gilbert and David Rosenthal
The Readout Loud
STAT
FT News Briefing
Financial Times
Global News Podcast
BBC World Service
Invest Like the Best with Patrick O'Shaughnessy
Colossus | Investing & Business Podcasts